Rituximab in indolent lymphomas.

Rituximab in indolent lymphomas.

Item
http://www.wikidata.org/entity/Q33764062
Immunogenic targets for specific immunotherapy in multiple myelomaA hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibodyPooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphomaA phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disordersRituximab: modes of action, remaining dispute and future perspective.Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines.Rituximab-induced early and late signaling have opposite effects on dexamethasone-induced apoptosis in human follicular lymphoma cells.The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
P2860

Rituximab in indolent lymphomas.

Item
http://www.wikidata.org/entity/Q33764062
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rituximab in indolent lymphomas.
@ast
Rituximab in indolent lymphomas.
@en
type
label
Rituximab in indolent lymphomas.
@ast
Rituximab in indolent lymphomas.
@en
prefLabel
Rituximab in indolent lymphomas.
@ast
Rituximab in indolent lymphomas.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Rituximab in indolent lymphomas.
@en
P2093
P2860
P304
P31
P356
10.1053/J.SEMINHEMATOL.2010.01.003
P433
P478
P577
P5875
P698
P932